Hanmi Pharmaceutical to acquire a remaining 80.07% stake in Aptose Biosciences for CAD2.41 per share.

Hanmi Pharmaceutical, a global biopharmaceutical company focused on developing innovative drugs in the fields of oncology, diabetes, obesity, and other metabolic diseases, agreed to acquire a remaining 80.07% stake in Aptose Biosciences, a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies, for CAD2.41 per share. “We are very pleased to have reached an agreement on a transaction with Hanmi. This transaction not only offers a premium value for our minority shareholders but also enables Aptose to continue the development of TUS combined with standard treatment venetoclax plus azacitidine (VEN+AZA) for acute myeloid leukemia (AML) in the TUSCANY Phase 1/2 clinical study. The TUS+VEN+AZA triplet therapy has shown promising response rates and safety in a diverse population of patients newly diagnosed with AML. We are extremely grateful for Hanmi’s ongoing support as we work toward our long-term goal of improving patient outcomes in AML,” William G. Rice, Ph.D., Aptose Chairman, President, and CEO.